34 completed, 5 unknown, 3 terminated, 1 active not recruiting. 21 Phase 4, 9 Phase 3, 7 Not applicable, 7 Phase 2.
Follow nepafenac: new trials by email Literature Review of nepafenac trials Research Report on nepafenac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis Nepafenac and lubricant, Placebo - Epiphora, Punctal Stenosis | Phase 4 | Active not recruiting | Instituto de Oftalmología Fundación Conde de Valenciana | 68 | 2026-01-12 | 2026-01-28 |
| Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery Bromfenac 0.09 % Ophthalmic Solution, Nepafenac 0.3% Oph Susp, diclofenac 0.1% ophthalmic susp. - Macular Oedema, Cataract Surgery | Not applicable | Recruiting | Nemocnice Kolín | 150 | 2025-08-01 | 2025-09-17 |
| Perioperative Topical Nepafenac After Epiretinal Membrane Surgery Nepafenac 0.1% Ophthalmic Suspension, Pars Plana Vitrectomy With Epiretinal Membrane and Internal Limiting Membrane Peeling - Epiretinal Membrane, Macular Pucker | Phase 4 | Completed | Ankara Yildirim Beyazıt University | 60 | 2024-01-01 | 2026-07-30 |
| Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy Nepafenac 0.1% eyedrops, Control (placebo) group - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 4 | Completed | Universitas Indonesia | 61 | 2021-04-28 | 2025-09-09 |
| CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops Nepafenac 0.1% Oph Susp, Refresh Tears 0.5% Lubricant Eye Drops - Congenital Hereditary Endothelial Dystrophy of Cornea | Phase 2 | Unknown | L.V. Prasad Eye Institute | 30 | 2020-12-15 | 2021-04-14 |
| Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract Phacoemulsification Bromfenac 0.09 % Ophthalmic Solution, Nepafenac 0.1% eyedrops, diclofenac 0.1% ophthalmic susp. - Pseudophakic Cystoid Macular Edema | Phase 4 | Completed | Pomeranian Medical University Szczecin | 88 | 2020-10-14 | 2026-07-10 |
| Post Intravitreal Injection Topical NSAID vs. Patching nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching - Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Phase 4 | Unknown | The New York Eye & Ear Infirmary | 60 | 2018-12-03 | 2019-04-17 |
| Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Difluprednate, Nepafenac, Prednisolone acetate - Uveitis, Macular Edema | Phase 4 | Terminated | University of California, San Francisco | 9 | 2018-09-12 | 2021-01-13 |
| PGE2 Levels in Patient Treated With NSAIDs Placebo, Dicloftil, Nevanac - Ocular Inflammation | Phase 3 | Completed | University of Trieste | 104 | 2018-04-25 | 2018-07-24 |
| Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference) - Cataract | Phase 3 | Completed | Actavis Inc. | 448 | 2018-03-28 | 2021-02-16 |
| Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections Nepafenac 0.1% Oph Susp, Nepafenac 0.3% Oph Susp, Artificial tear - Pain | Not applicable | Completed | University Hospital of Patras | 99 | 2017-09-01 | 2018-04-04 |
| Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy Dexamethasone Disodium Phosphate 0.1%, Nepafenac 0.1%, Hydroxyethylcellulose 0.19% - Glaucoma, Closed-Angle, Glaucoma, Narrow-Angle | Not applicable | Unknown | Sheba Medical Center | 100 | 2016-11-01 | 2018-04-24 |
| Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections Nepafenac Eye Drops, Placebo (Artificial Tears) - Pain | Not applicable | Completed | University Hospital of Patras | 55 | 2016-06-01 | 2017-05-05 |
| Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5% nepafenac 0.3%, ketorolac - Cataract | Not applicable | Completed | MDbackline, LLC | 200 | 2016-04-01 | 2017-03-07 |
| Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort Diclofenac, Nepafenac - Post Surgical Management, Pain Management | Not applicable | Unknown | Wolfson Medical Center | 30 | 2015-07-01 | 2015-07-24 |
| Dropless vs. Standard Drops Contralateral Eye Study TriMoxiVanc, Moxifloxacin HCl 0.5%, Ilevro - Cataract | Phase 4 | Completed | Carolina Eyecare Physicians, LLC | 59 | 2015-01-01 | 2018-02-23 |
| NSAIDs and PGE2 Levels in Vitrectomy Patients Ketorolac 0.5% eyedrops, Indomethacin 0.5% eyedrops, Bromfenac 0.09% eyedrops - Vitreous Inflammation | Phase 3 | Completed | Università degli Studi di Brescia | 70 | 2014-03-01 | 2015-02-12 |
| Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification PRO-155, Nevanac - Cataract, Phacoemulsification Cataract Surgery | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 160 | 2013-12-01 | 2018-10-30 |
| Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial Bromfenac, Nepafenac - Treatment of Ocular Inflammation Associated With Cataract Surgery | Phase 4 | Completed | Silverstein Eye Centers | 57 | 2013-10-30 | 2019-04-01 |
| Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification Nepafenac, Ketorolac - Cystoid Macular Edema, Cataract | Phase 4 | Completed | Hospital Oftalmologico de Brasilia | 40 | 2013-08-01 | 2014-03-12 |
Showing 20 of 44. Sign in to see all of them.
Cataract (16) · Macular Edema (12) · Pain (5) · Diabetic Retinopathy (3) · Inflammation (3) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Epiretinal Membrane (2) · Agnosia (1) · Constriction, Pathologic (1) · Corneal Dystrophy, Posterior Polymorphous, 1 (1) · Corneal Opacity (1) · Glaucoma, Angle-Closure (1) · Hyperopia (1) · Lacrimal Apparatus Diseases (1)
Alcon Research (7) · Innovative Medical (3) · Frank A. Bucci, Jr., M.D. (2) · University Hospital of Patras (2) · Actavis Inc. (1) · Ankara Yildirim Beyazıt University (1) · Asociación para Evitar la Ceguera en México (1) · Bp Consulting, Inc (1) · Carolina Eyecare Physicians, LLC (1) · Center For Excellence In Eye Care (1) · Dr T V Patel Eye Institute (1) · Federal University of São Paulo (1) · Hospital Juarez de Mexico (1) · Hospital Oftalmologico de Brasilia (1) · Instituto de Oftalmología Fundación Conde de Valenciana (1)
United States (15) · Mexico (4) · Brazil (3) · India (3) · Greece (2) · Israel (2) · Czechia (1) · France (1) · Indonesia (1) · Italy (1) · Malaysia (1) · Poland (1) · Turkey (Türkiye) (1)
William Trattler, MD (2) · Ari Djatikusumo, MD (1) · Ari Leshno, MD (1) · Constantine D Georgakopoulos, MD, Phd (1) · Constantine Georgakopoulos, MD, PhD (1) · Dana Sager, MS (1) · Dulce O Rascon-Vargas, Fellow (1) · Francis Mah, MD (1) · Frank A Bucci, Jr., MD (1) · Frank A Bucci, Jr.,, MD (1) · Guadalupe Cervantes-Coste (1) · Gustavo T Grottone, MD, MBA,MSc (1) · Jans Fromow-Guerra (1)
PMID 27388251, PMID 11320025, PMID 11320034, PMID 11820911, PMID 14452301, PMID 14508260, PMID 14644218, PMID 16196117, PMID 16488953, PMID 18165083, PMID 18609466, PMID 18664937, PMID 18806663, PMID 19668532, PMID 20142967, PMID 20216291, PMID 21187730, PMID 21386741, PMID 21982102, PMID 22241928, PMID 2243969, PMID 22848141, PMID 22927737, PMID 24345529, PMID 24935281, PMID 25215411, PMID 25385061, PMID 25602634, PMID 27536206, PMID 27911445, PMID 28574492, PMID 29375191, PMID 30270476, PMID 30325678, PMID 30868419, PMID 31552543, PMID 32317792, PMID 32546955, PMID 33595256, PMID 3390040, PMID 35111339, PMID 36311352, PMID 36470407, PMID 3729781, PMID 37463348, PMID 37641620, PMID 6059676, PMID 8217962, PMID 8306663, PMID 9599360
2005 (1), U10EY014231 (1), U10EY018817 (1)